Prophylactic activity of biogenic selenium nanoparticles against chronic Toxoplasma gondii infection.

CONCLUSION: The results of the present study showed a new patent in the treatment of toxoplasmosis; so that taking the biogenic selenium nanoparticles in concentrations of 2.5-10 mg/kg for 2 weeks was able to prevent severe symptoms of the toxoplasmosis in mice model. This indicated the prophylactic effects of SeNPs with no considerable toxicity against latent toxoplasmosis. However, more studies are required to elucidate the correct anti-Toxoplasma mechanisms of SeNPs. PMID: 32496989 [PubMed - as supplied by publisher]
Source: Recent Patents on Anti-Infective Drug Discovery - Category: Infectious Diseases Tags: Recent Pat Antiinfect Drug Discov Source Type: research